Patient selection for implantation of a cardioverter-defibrillator for primary prevention of sudden cardiac death is especially difficult in inherited arrhythmia syndromes, owing to a lack of randomized outcome studies in this setting. Two registry studies and the first report of a long-term follow-up of defibrillators in primary prophylaxis have provided some information regarding patient selection, but have important limitations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Epstein, A. E. et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 117, e350–e408 (2008).
Moss, A. J. et al. for the MADIT Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346, 877–883 (2002).
Myerburg, R. J. Sudden cardiac death: exploring the limits of our knowledge. J. Cardiovasc. Electrophysiol. 12, 369–381 (2001).
Schwartz, P. J. et al. Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation 122, 1272–1282 (2010).
Corrado, D. et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation 122, 1144–1152 (2010).
Goldenberg, I. et al. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 122, 1265–1271 (2010).
Dorian, P. Effective and efficient use of implantable defibrillators: sometimes it's over when it's over. CMAJ 180, 599–600 (2009).
Ellenbogen, K. A. et al. for the DEFINITE Investigators. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomypathy? Circulation 113, 776–782 (2006).
Bardy, G. H. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352, 225–237 (2005).
Packer, D. L. et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation 120, 2170–2176 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Pinter, A., Dorian, P. Who may and who may not benefit from an ICD?. Nat Rev Cardiol 8, 10–12 (2011). https://doi.org/10.1038/nrcardio.2010.183
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2010.183
This article is cited by
-
Effective communication and ethical consent in decisions related to ICDs
Nature Reviews Cardiology (2011)